Klonopin and Xanax are both benzodiazepines that reduce anxiety and panic.
They differ in half-life, onset speed, approved indications, and the clinical profile of their respective dependence and withdrawal presentations in ways that directly affect addiction risk and recovery approach.
Klonopin (clonazepam) has a half-life of 18 to 50 hours; Xanax (alprazolam) has a half-life of 6 to 27 hours. This pharmacokinetic difference shapes how quickly each drug produces euphoric effects, how rapidly dependence develops, and how medical detoxification must be managed.
Key Takeaways
- Klonopin and Xanax are both DEA Schedule IV benzodiazepines, but Xanax’s shorter half-life produces faster onset of effect and euphoric reward, driving higher rates of non-medical use and more severe interdose withdrawal symptoms.
- Benzodiazepines were involved in 14,937 overdose deaths in the U.S. in 2022, with the majority involving co-administered opioids, according to CDC NCHS data.
- Neither Klonopin nor Xanax is recommended for long-term use by FDA prescribing guidelines; both produce physical dependence within weeks of daily use regardless of dose.
- The Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) guides clinical management of both Klonopin and Xanax withdrawal, with long-acting benzodiazepine substitution (typically diazepam or chlordiazepoxide) as the primary pharmacological approach.
- Approximately 5.6 million Americans met DSM-5-TR criteria for sedative-hypnotic or anxiolytic use disorder in 2022, according to SAMHSA’s National Survey on Drug Use and Health.
What Is Klonopin (Clonazepam)?
Klonopin is the brand name for clonazepam, a long-acting benzodiazepine FDA-approved for panic disorder (with or without agoraphobia), Lennox-Gastaut syndrome seizure control, and absence and myoclonic seizure management. Its half-life of 18 to 50 hours means a single dose maintains therapeutic benzodiazepine receptor occupancy for 1 to 2 days.
Klonopin Pharmacology
- Active ingredient: Clonazepam
- Mechanism: Positive allosteric modulator at GABA-A receptors containing alpha-1, alpha-2, alpha-3, and alpha-5 subunits; increases frequency of chloride channel opening in response to GABA
- Half-life: 18 to 50 hours (active; no active metabolites)
- Onset: 20 to 60 minutes after oral administration
- Available strengths: 0.5mg, 1mg, 2mg tablets; 0.125mg, 0.25mg, 0.5mg, 1mg, 2mg orally disintegrating wafers
- FDA-approved indications: Panic disorder, Lennox-Gastaut syndrome, akinetic and myoclonic seizures
- DEA classification: Schedule IV
What Is Xanax (Alprazolam)?
Xanax is the brand name for alprazolam, a high-potency, intermediate-acting benzodiazepine FDA-approved for generalized anxiety disorder (GAD) and panic disorder. Its 6 to 27-hour half-life, combined with a rapid oral absorption profile, produces a faster and more pronounced onset of anxiolysis and euphoria than Klonopin, driving higher rates of non-medical use.
Xanax Pharmacology
- Active ingredient: Alprazolam
- Mechanism: Positive allosteric modulator at GABA-A receptors; like clonazepam, potentiates chloride ionophore activity via benzodiazepine binding site
- Half-life: 6 to 27 hours (alpha-hydroxyalprazolam active metabolite: 12 to 15 hours)
- Onset: 15 to 30 minutes after oral administration
- Available strengths: 0.25mg, 0.5mg, 1mg, 2mg tablets; XR formulation available
- FDA-approved indications: Generalized anxiety disorder, panic disorder
- DEA classification: Schedule IV
Klonopin vs. Xanax: Full Comparison
Both medications potentiate GABA-A receptors through the same benzodiazepine binding site, but their pharmacokinetic and pharmacodynamic profiles diverge in clinically meaningful ways.
| Feature | Klonopin (Clonazepam) | Xanax (Alprazolam) |
|---|---|---|
| Active ingredient | Clonazepam | Alprazolam |
| Half-life | 18–50 hours | 6–27 hours |
| Onset | 20–60 minutes | 15–30 minutes |
| Duration of action | 6–12 hours | 4–6 hours |
| FDA indications | Panic disorder, seizure disorders | GAD, panic disorder |
| Potency (vs diazepam) | 20x (0.5mg clonazepam = 10mg diazepam) | 10x (1mg alprazolam = 10mg diazepam) |
| Non-medical use rate | Lower (slower onset reduces reinforcement) | Higher (faster onset increases reward signal) |
| Withdrawal severity | Moderate to severe; slower onset (48–72 hrs) | Severe; faster onset (12–24 hrs); interdose rebound |
| DEA Schedule | IV | IV |
Causes and Risk Factors for Benzodiazepine Use Disorder
Both Klonopin and Xanax produce physical dependence through GABA-A receptor neuroadaptation that begins within weeks of regular use regardless of whether the prescription is being taken as directed. Dr. Heather Ashton, whose Ashton Manual remains the clinical reference for benzodiazepine tapering protocols, documented that dependence at therapeutic doses is not equivalent to addiction but produces a physiological state requiring structured discontinuation to avoid withdrawal seizures.
Neurobiological Risk Factors
- GABA-A receptor downregulation: Chronic benzodiazepine exposure reduces GABA-A receptor density and sensitivity; when the drug is removed, the resulting GABA inhibitory deficit produces CNS hyperexcitability manifesting as anxiety, insomnia, tremors, and seizures
- Dopaminergic reinforcement: Alprazolam (Xanax) produces greater dopamine release in the nucleus accumbens than clonazepam due to its faster onset and higher potency-to-half-life ratio, explaining higher rates of non-medical use and compulsive redosing
- Genetic vulnerability: Family history of alcohol use disorder increases benzodiazepine dependence risk through shared neurobiological vulnerabilities in GABAergic inhibitory tone regulation
Psychiatric and Social Risk Factors
- Anxiety disorder comorbidity: Both Klonopin and Xanax are prescribed for anxiety; patients with anxiety disorders have higher rates of long-term benzodiazepine use because cessation triggers the return of anxiety that is indistinguishable from withdrawal-induced anxiety rebound
- Trauma and PTSD: PTSD is a significant risk factor for benzodiazepine misuse; benzodiazepines reduce hyperarousal symptoms short-term while paradoxically impairing fear extinction processing and prolonging PTSD course
- Polysubstance co-use: Alcohol and opioid co-use dramatically increases benzodiazepine overdose risk; approximately 30 percent of opioid overdose deaths also involve a benzodiazepine
Klonopin vs. Xanax Withdrawal: Clinical Differences
The most clinically significant difference between Klonopin and Xanax is the withdrawal timeline, with Xanax’s shorter half-life producing more intense and rapidly escalating interdose rebound anxiety and earlier onset of life-threatening withdrawal symptoms.
Xanax Withdrawal
Alprazolam withdrawal begins within 12 to 24 hours of the last dose due to its short half-life, peaks at 24 to 72 hours, and in daily high-dose users produces severe autonomic instability, seizures, and delirium requiring inpatient management. The Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) quantifies withdrawal severity and guides pharmacological escalation.
- Interdose rebound: Xanax users experience mini-withdrawal episodes between prescribed doses, producing anxiety surges that drive compulsive redosing and dose escalation independent of the underlying anxiety disorder
- Seizure risk: High-dose abrupt alprazolam discontinuation carries seizure risk comparable to alcohol withdrawal, requiring medical supervision with long-acting benzodiazepine substitution and gradual taper
- PAWS: Post-acute withdrawal syndrome persists for weeks to months after acute alprazolam detox, producing protracted anxiety, insomnia, and cognitive fog that requires ongoing clinical support
Klonopin Withdrawal
Clonazepam withdrawal begins more slowly (48 to 72 hours after last dose) due to its longer half-life, producing a more gradual but equally severe withdrawal syndrome that can persist for weeks and require extended tapering protocols lasting 3 to 12 months.
- Extended taper requirement: The Ashton Manual recommends a diazepam substitution approach for clonazepam withdrawal, converting to an equivalent diazepam dose and tapering by no more than 10 percent per 2-week period
- Cognitive effects: Chronic clonazepam use produces measurable deficits in verbal memory, attention, and processing speed that may take 3 to 6 months to recover after cessation
- Seizure risk: Abrupt clonazepam discontinuation after high-dose chronic use carries generalized seizure risk; the longer half-life compresses the acute seizure risk window but does not eliminate it
Benzodiazepine Use Disorder Treatment at Riverside Recovery of Tampa
Benzodiazepine use disorder from Klonopin or Xanax requires medically supervised detoxification that never involves abrupt discontinuation. At Riverside Recovery’s medical detox unit, benzodiazepine withdrawal is managed with CIWA-B-guided diazepam or chlordiazepoxide substitution and gradual taper under 24-hour clinical supervision.
Assistant Medical Director Erin Ikenberry, PA-C, notes: “Xanax presentations are among the most challenging because the short half-life means patients arrive already in early withdrawal, which puts us in a reactive clinical position. Klonopin presentations give us a slightly wider window, but both require the same commitment to a structured substitution taper rather than any form of abrupt discontinuation.”
Residential treatment following detox addresses the anxiety, panic disorder, and PTSD that typically underlie chronic benzodiazepine use, using CBT, DBT, and EMDR through evidence-based therapy programming. Dual diagnosis evaluation within 72 hours identifies co-occurring conditions requiring non-benzodiazepine pharmacological management. Step-down care through IOP and all programs available with same-day assessment at (800) 871-5440.
Frequently Asked Questions
Is Klonopin stronger than Xanax?
By milligram-to-milligram potency, Klonopin is stronger: 0.5mg clonazepam equals approximately 10mg diazepam, while 1mg alprazolam equals approximately 10mg diazepam. However, Xanax produces a faster and more intense subjective effect due to its shorter half-life and more rapid onset, which increases its reinforcing properties and non-medical use rate compared to Klonopin despite lower milligram potency.
Can you take Klonopin and Xanax together?
Combining Klonopin and Xanax is medically dangerous and not clinically indicated. Both drugs potentiate GABA-A receptors at the same binding site; combining them produces additive CNS depression with compounded respiratory suppression risk. No FDA-approved indication requires co-prescribing two benzodiazepines simultaneously. If both are present together, it indicates non-prescribed use or a prescribing error.
Which is more addictive, Klonopin or Xanax?
Xanax (alprazolam) has higher addiction potential due to its shorter half-life, faster onset of euphoric effect, and the interdose rebound anxiety that drives compulsive redosing. Klonopin produces physical dependence equally quickly but its slower onset and longer duration produce a less reinforcing dopaminergic reward signal. Both are Schedule IV controlled substances with high misuse rates relative to other anxiolytics.
How long does Klonopin withdrawal last?
Klonopin withdrawal begins 48 to 72 hours after the last dose due to its long half-life, with acute symptoms peaking in the first week and resolving over 2 to 4 weeks for short-term users. Chronic high-dose users may experience protracted post-acute withdrawal syndrome for 3 to 12 months including persistent anxiety, insomnia, and cognitive fog. A structured diazepam substitution taper managed by a clinician is the safest approach.
What is the difference between Klonopin and Xanax for anxiety?
Both FDA-approved for panic disorder, they differ in practical use: Xanax’s faster onset makes it more effective for acute panic attack relief, while Klonopin’s longer duration makes it suitable for ongoing anxiety management requiring stable blood levels. Neither is recommended for long-term anxiety treatment due to dependence risk; SSRIs, SNRIs, and buspirone are first-line long-term options.
Are Klonopin and Xanax the same drug?
No. Klonopin contains clonazepam and Xanax contains alprazolam; these are two different chemical compounds that share the benzodiazepine class mechanism but have distinct half-lives, potencies, approved indications, and clinical profiles. They are not interchangeable and should not be substituted for one another without clinical supervision.
References
- Ashton, C. H. (2002). Benzodiazepines: How they work and how to withdraw (The Ashton Manual). University of Newcastle upon Tyne. Retrieved from benzo.org.uk
- Centers for Disease Control and Prevention, National Center for Health Statistics. (2023). Drug overdose deaths in the United States, 2001–2022. NCHS Data Brief No. 491.
- Substance Abuse and Mental Health Services Administration. (2023). National Survey on Drug Use and Health, 2022 results. U.S. Department of Health and Human Services.
- Dell’osso, B., & Lader, M. (2013). Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. European Psychiatry, 28(1), 7–20.
- American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Publishing.
- Drug Enforcement Administration. (2023). Benzodiazepines drug fact sheet. U.S. Department of Justice.
- Lader, M. (2011). Benzodiazepines revisited: Will we ever learn? Addiction, 106(12), 2086–2109.